StreetInsider.com News Articles

SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies

Wed, 02 Sep 2026 08:17:00 -0400

This strategic engagement is designed to strengthen NeuroThera’s U.S. market position, visibility among key U.S. federal stakeholders, reinforce the clinical and public‑health importance of advancing new treatment options for adult Tourette Syndrome

TEL AVIV, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, today announced that it is pursuing U.S. Food and Drug Administration (“FDA”) Orphan Drug Designation covering SCI-110, its drug candidate for the treatment

SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies

Wed, 02 Sep 2026 08:17:00 -0400

SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies

Wed, 02 Sep 2026 08:17:00 -0400

SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies

Wed, 02 Sep 2026 08:17:00 -0400

SciSparc autism trial enrolls 26 of 60 planned children for SCI-210

Mon, 31 Aug 2026 16:03:24 -0400

SciSparc Ltd. (NASDAQ: SPRC) announced that its subsidiary NeuroThera Labs Inc. has enrolled 26 children in a clinical trial evaluating SCI-210, a treatment for autism spectrum disorder, according to a press release.

The trial, conducted at Soroka Medical Center in Israel, is a double-blind, randomized, placebo-controlled study targeting a total of 60 participants between the ages of five and 18. Each participant will receive treatment over a 20-week period.

SCI-210 combines cannabidiol (CBD) with CannAmide™, NeuroThera's proprietary Palmitoylethanolamide-based formulation. The trial is designed to compare SCI-210 against CBD monotherapy to assess whether the dual-compound approach offers additional benefit.

Primary efficacy endpoints include the

SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial

Mon, 31 Aug 2026 16:03:00 -0400

TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, continued advancement in participant enrollment for the clinical trial assessing NeuroThera’s innovative SCI-210 treatment for symptoms associated with autism spectrum disorder (“ASD”).

The clinical trial, conducted at Soroka Medical Center in Israel, is a double-blind, randomized, placebo-controlled study evaluating the safety and efficacy of SCI-210 in children diagnosed with ASD. To date, 26 children have been enrolled,

SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial

Mon, 31 Aug 2026 16:03:00 -0400

SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial

Mon, 31 Aug 2026 16:03:00 -0400

SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial

Mon, 31 Aug 2026 16:03:00 -0400

Form 6-K SciSparc Ltd. For: Aug 26

Wed, 26 Aug 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260826/26981408.html

Form 6-K SciSparc Ltd. For: Aug 26

Wed, 26 Aug 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260826/26981408.html

SciSparc adds Technion AI professor to advisory board

Wed, 26 Aug 2026 08:32:13 -0400

SciSparc Ltd. (NASDAQ: SPRC) announced the addition of Prof. Carmel Domshlak, a professor at the Technion – Israel Institute of Technology, to its Scientific Advisory Board for AI and Cybersecurity, effective September 1, 2026.

The appointment follows a July 27, 2026, announcement in which SciSparc's board of directors decided to target the Agentic AI market and establish the advisory board. The company stated it is evaluating opportunities in the Agentic AI field and is in discussions with several companies active in the market.

Prof. Domshlak joined the Technion faculty in 2003 and served as Dean of the Faculty from 2017 to 2021.

SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board

Wed, 26 Aug 2026 08:32:00 -0400

The addition of leading AI researcher further strengthens SciSparc’s scientific and technical foundation as the Company advances its strategic focus on the Agentic AI market

TEL AVIV, Israel, Aug. 26, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced the addition of Prof. Carmel Domshlak, an internationally recognized artificial intelligence (“AI”) expert and professor at the Technion – Israel Institute of Technology (“Technion”), to the Company’s newly established Scientific Advisory Board for AI and Cybersecurity, effective September 1, 2026.

Prof. Domshlak’s addition represents a further step in SciSparc’s efforts to build

SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board

Wed, 26 Aug 2026 08:32:00 -0400

The addition of leading AI researcher further strengthens SciSparc’s scientific and technical foundation as the Company advances its strategic focus on the Agentic AI market

Prof. Domshlak’s addition represents a further step in SciSparc’s efforts to build

SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board

Wed, 26 Aug 2026 08:32:00 -0400

The addition of leading AI researcher further strengthens SciSparc’s scientific and technical foundation as the Company advances its strategic focus on the Agentic AI market

Prof. Domshlak’s addition represents a further step in SciSparc’s efforts to build

SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board

Wed, 26 Aug 2026 08:32:00 -0400

The addition of leading AI researcher further strengthens SciSparc’s scientific and technical foundation as the Company advances its strategic focus on the Agentic AI market

Prof. Domshlak’s addition represents a further step in SciSparc’s efforts to build

Form 6-K SciSparc Ltd. For: Aug 24

Mon, 24 Aug 2026 09:22:00 -0400

si-local-file:///var/storage/secattach/20260824/26965130.html

Form 6-K SciSparc Ltd. For: Aug 24

Mon, 24 Aug 2026 09:22:00 -0400

si-local-file:///var/storage/secattach/20260824/26965130.html

SciSparc unit files U.S. patent for MDMA-PEA combination for PTSD

Mon, 24 Aug 2026 08:51:51 -0400

SciSparc Ltd. (NASDAQ: SPRC) announced that its subsidiary, NeuroThera Labs Inc. (TSXV: NTLX), and its collaborator Clearmind Medicine Inc. (NASDAQ: CMND) have had a U.S. patent application published covering a combination of MDMA and N-acylethanolamines, such as palmitoylethanolamide (PEA), for potential use in treating post-traumatic stress disorder, anxiety, and eating disorders.

The United States Patent and Trademark Office published the application, which covers embodiments relating to the potential use of PEA in combination with MDMA, including potential effects on therapeutic potency, required dosing, side effects, and therapeutic window.

According to the company's statement, the collaboration between NeuroThera and Clearmind has generated a

SciSparc unit files U.S. patent for MDMA-PEA combination for PTSD

Mon, 24 Aug 2026 08:51:51 -0400

According to the company's statement, the collaboration between NeuroThera and Clearmind has generated a

SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation